top of page

OUR JOURNEY

Silica Corpora was born as a result of the main purpose of the founders, Timofei and Jaime, to respond to challenges in drug discovery exploiting recent advances in computational technologies.

OUR MISSION

Design, not discovery

The estimated cost of bringing a new prescription drug to the market has risen dramatically from $1.1B in 2003 to $2.3B in 2019 while early stages of drug discovery take around 3 years. The replacement of lead generation and lead optimization stages of antibody drug discovery with AI may reduce the times and costs of early antibody discovery by 10-100 times while improving its quality and accuracy.

"Our mission is to develop tailored AI-solutions to develop more-quality and more cost-effective antibody therapeutics, turning historical data of previous Drug Discovery projects into valuable assets, significantly reducing the prospective sunk costs."

0F4A5953.jpg

Our Team

Our expertise supports our results

Our Journey So Far

September 2022

SILICA CORPORA IS FOUNDED

Jaime and Tim started the company when they received financing from REACT Scholarship, a Startup Incubator Berlin (SIB) program for health tech Start-ups.

March 2023

FIRST MVP COMPLETION

In this stage, our platform can generate CDRs from scratch, given a target sequence and epitope. Moreover, the platform is capable of binding affinity optimization given sequences of a target and antibody candidates. 

Acetohydroxyacid Synthase     https___pdb101.rcsb_edited.jpg
bottom of page